ViroPharma Looks To Enter HAE Market With Lev Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.